InnoCare Pharma and Keymed Biosciences jointly announced that the first subject has been dosed in clinical trial of ICP-B05 (CM369), an anti-CC chemokine receptor 8 (CCR8) monoclonal antibody, developed by a joint venture between the two companies called Tiannuojiancheng Pharma in China. ICP-B05 is a potential first-in-class drug co-developed by InnoCare and Keymed as a monotherapy or in combination with other therapies for the treatment of various cancers. There are no CCR8-targeted drugs in the world.

ICP-B05 selectively depletes Tregs in the tumor microenvironment, which is more specific than other immunotherapies. CM369 binds to CCR8 on Tregs and eradicates immunosuppressive Tregs through ADCC to augment the anti-tumor immunity in TME while preserving peripheral homeostasis. CM369 has the potential to deliver optimal tumor targeted Treg depletion and be more specific in anti-tumor activity than other immunotherapies.